Date: 2014-07-07
Type of information: Milestone
Compound: monoclonal antibodies specific to an undisclosed oncology target
Company: BioInvent (Sweden) Servier (France)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism:
Disease: undisclosed cancer
Details: * On January 4, 2012, BioInvent International and Servier have entered into an antibody collaboration on an oncology target involved in tumour cell metabolism provided by Servier. Under the terms of the agreement Servier will engage BioInvent to screen its proprietary n-CoDeR® library for antibodies specific to the undisclosed target. Servier will also have access to BioInvent\'s in-house pre-clinical capacities in selecting an antibody candidate for development. The Bioinvent n-CoDeR® library will be used in combination with a functional assay set up at Servier to select antibody candidates. This is expected to enable Servier to develop one of the first monoclonal antibodies targeting tumour cell metabolism.
Financial terms: BioInvent will receive a licensing fee, research support and potential milestone payments of more than € 11m, as well as royalty on future sales of the product.
Latest news: * On July 7, 2014, BioInvent International announced that it has received two separate milestone payments, together worth € 1 million, as a result of milestones being reached under collaborations with Bayer Pharma and Servier. The milestone payment from Servier was due as antibodies identified from the n-CoDeR® library against an undisclosed target structure provided by Servier have reached in vivo proof of concept. According to the agreement signed by the parties in 2012, Servier has access to BioInvent’s preclinical expertise in optimizing antibody candidates for further clinical development. Specific milestone payments were not disclosed.
